Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942926 | 0.86 | ACHE (0.41) | ACHETSHR | |
| SCHEMBL635149 | 0.82 | HDAC1 (0.37) | ACHETSHRDAO | |
| SCHEMBL1125635 | 0.78 | ALDH1A1 (0.40) | ACHETSHRSMN1; SMN2 | |
| SCHEMBL667921 | 0.78 | CES2 (0.36) | — | |
| SCHEMBL6650984 | 0.77 | ACHE (0.37) | ACHEGABRA1SIGMAR1PTGS2HTR2A | |
| Bromide SCHEMBL733561 | 0.76 | CES2 (0.34) | — | |
| SCHEMBL18009876 | 0.74 | VCP (0.35) | SLC9A1 | |
| SCHEMBL19031224 | 0.73 | — | — | |
| SCHEMBL30702572 | 0.73 | TSHR (0.35) | PTGS2HTR2BTSHRSMN1; SMN2SLC6A2 | |
| SCHEMBL665988 | 0.73 | SLC2A1 (0.39) | TSHRSMN1; SMN2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| CN-117881664-A | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as NAV1.8 inhibitors | 默沙东有限责任公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11945836-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4334293-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20220380338-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2022235859-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-11-10 | — | — | WO | disclosed |
| US-4710513-A | Substituted pyranone inhibitors of cholesterol synthesis | MERCK & CO., INC. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0216127-A2 | 6-Phenoxymethyl-4-hydroxytetrahydropyran-2-ones, process for their preparation, their use as medicines, pharmaceutical compositions and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-01 | — | — | EP | disclosed |
| US-4567289-A | ANTICHOLESTEROL ANTILIPEMIC | MERCK & CO., INC. (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0038061-B1 | SUBSTITUTED BIPHENYL-2-CARBOXALDEHYDES AND A PROCESS FOR PREPARING THEM | MERCK & CO. INC. (US) | 1985-01-23 | — | — | EP | disclosed |
| US-4459422-A | Substituted pyranone inhibitors of cholesterol synthesis | MERCK & CO., INC. (US) | 1984-07-10 | — | — | US | disclosed |
| US-4375475-A | ANTICHOLESTEROL AGENTS | MERCK & CO., INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4322563-A | Substituted biphenyl-2-carboxaldehydes | MERCK & CO., INC. (US) | 1982-03-30 | — | — | US | disclosed |
| EP-0038061-A1 | Substituted biphenyl-2-carboxaldehydes and a process for preparing them | MERCK & CO. INC. (US) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945836-B2 | Compositions and methods for treating CNS disorders | GRIN2B, ADRA2B, ADRA1B | ACHE 188/4885GABRA1 13/4885SIGMAR1 123/4885 |
| US-20230279043-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ACHE 188/4885GABRA1 13/4885SIGMAR1 123/4885 |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ACHE 188/4885GABRA1 13/4885SIGMAR1 123/4885 |
| US-20220380338-A1 | CYCLOALKYL 3-OXOPIPERAZINE CARBOXAMIDES AND CYCLOHETEROALKYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | ACHE 460/4885GABRA1 1671/4885SIGMAR1 969/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | ACHE 4145/4885GABRA1 1060/4885SIGMAR1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.